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ABSTRACT 
Background and objectives: In recent years, Clostridium difficile infection has become 
more common and more resistant to therapy resulting in significant in-patient morbidity and 
mortality. The aim of this study was to describe the characteristics of patients with 
Clostridium difficile infection at the Charlotte Maxeke Johannesburg Academic Hospital 
(CMJAH) in Johannesburg, South Africa. 
Methods:  This was a retrospective analysis of the records of 154 adult in-patients with 
confirmed Clostridium difficile infection on stool samples during the period 1 January 2013 
to 30 June 2014. Patient demographics, clinical presentation, risk factors, HIV status, 
treatment, severity indicators and outcomes were analysed. Patients were catagorised as 
having either healthcare-associated or community-acquired Clostridium difficile infections. 
HIV-positive patients were compared with HIV-negative patients and the survivors were 
compared with the non-survivors. 
Results: Overall, 83 (53.8%) patients were female and the median age was 39 years 
(Interquartile range: 31-52). The most common symptom was watery diarrhoea (92.9%) 
followed by fever (27.3%). Overall, 145 (97.9%) patients had been exposed to antibiotics in 
the last 30 days, 54 (35.1%) to immunosuppressives, 48 (31.2%) to gastric acid suppressants 
and 65 (42.2%) patients had previous hospital admissions. In total 73 (47.4%) patients died. 
Only two cases of community-acquired Clostridium difficile infections were identified. There 
was no difference in outcomes of HIV-positive patients compared to HIV-negative patients. 
The non-survivors tended to have a greater number of severity indicators compared to the 
survivors. 
Conclusion: Patients with Clostridium difficile infection in this study were younger than 
expected with a higher mortality than that reported in the Western world. The number of 
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community-acquired Clostridium difficile infections was less than reported in previous 
studies.  
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1.0 INTRODUCTION 
Clostridium difficile infection is an important cause of in-patient morbidity and mortality. 
Over recent years the infection has become more common with an increase in resistance to 
therapy and frequent recurrence. For this reason it has become more important to increase our 
understanding of this infection in our patient population. There are very little local data 
available on this subject and the aim of this study was to gain more information regarding the 
demographic characteristics, common presenting clinical features and identifiable risk 
factors, treatment and outcomes of patients in Johannesburg, South Africa. The study was a 
retrospective record review of adult (≥18 years) in-patients at the Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH) with confirmed Clostridium difficile infection. 
Such a study has not been done previously in Johannesburg. 
1.1 The organism 
Clostridium difficile (CD) is an anaerobic bacillus which stains Gram positive and is known 
to be spore forming. The organism can asymptomatically colonize the gut or cause a 
spectrum of disease from mild diarrhoea to extensive pseudomembranous colitis, toxic 
megacolon and bowel perforation (Rajabally et al. 2013). The CD spores are ingested and 
germinate in the small intestine where they produce exotoxins which cause mucosal damage 
and colitis (Gould & McDonald 2008). CD does not directly invade the colon and infection 
outside of the colon is extremely rare (Leffler & Lamont 2015). 
1.2 Risk factors 
1.2.1 Drugs 
One of the major risk factors for Clostridium difficile infection is exposure to antibiotics in 
the prior 30 days. The most commonly associated antibiotics include the fluoroquinolones, 
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cephalosporins and clindamycin. These antibiotics cause CD overgrowth and toxin 
production in the gut by disturbing the normal gut flora. Similarly, prolonged hospital stays 
increase the risk of CD due to extensive antibiotic use (Bobo, Dubberke & Kollef 2011). One 
study found that 75% of cases of hospital-acquired CD infections were identified on the 7
th
 
day of admission, and only 2.8% and 5.5% were identified on the 3
rd
 and 4
th
 days of 
admission respectively (Oake, et al. 2010).  
In 2010, a study documented that gastric acid suppression increased the risk for nosocomial 
CD infection (Howell et al. 2010). The risk of CD infection without acid suppressants was 
found to be 0.3% versus 0.6% in patients on a histamine 2 (H2) receptor antagonist and 0.9% 
in patients on daily proton pump inhibitors (PPIs). The risk in patients on more frequent than 
daily PPIs was found to be 1.4%. It is speculated that this is due to vegetative forms of CD 
that are able to survive longer with neutralization of gastric acid (Freedberg et al. 2010; 
Linsky et al. 2013). 
Immunosuppressive therapies, including chemotherapy and radiation therapy, also increase 
the risk of CD infection. Drugs that result in intestinal stasis (such as opiates and loperamide) 
may also increase the risk of CD infection (Bobo, Dubberke & Kollef 2011). Furthermore, 
The British Journal of Pharmacology published a study which demonstrated that diclofenac is 
associated with a 35% increased risk of CD-associated disease in non-hospitalized patients 
(Suissa et al. 2012). This was not found with the use of other non-steroidal anti-inflammatory 
drugs (NSAIDs).  
Another study suggested that depression and/or the use of certain anti-depressants (namely 
mirtazapine, fluoxetine and nortriptyline) are associated with the development of CD 
infection (Rogers et al. 2013). In the same study, being widowed or living alone were also 
suggested risk factors for CD infection. The study suggested that this is because these 
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patients were more likely to have depressive symptoms which have been shown to cause an 
increased and prolonged inflammatory response and immune dysregulation. Furthermore, 
bereavement has been shown to decrease neutrophil production of superoxide radicles and to 
reduce the functional capacity of natural killer cells. Therefore, the increased risk of CD 
infection may be related to the physiological changes in depression rather than the use of 
anti-depressants (Rogers et al. 2013). 
1.2.2 Host factors 
Obesity has been identified as a risk for CD infection. In a study from 2013, the mean BMI of 
patients who acquired CD infections was 33.6 versus 28.9 in the control group (Jihad et al. 
2013). As mentioned previously, depression is also a host-related risk factor (Rogers et al. 
2013). Other host factors include age ≥65 years, multiple comorbidities, peri-partum females, 
inflammatory bowel disease, chronic kidney disease requiring haemodialysis and human 
immunodeficiency virus (HIV) infection (Bobo, Dubberke & Kollef. 2011).  
1.2.3 HIV infection 
The risk of CD infection in HIV-positive individuals is twice that of HIV-negative 
individuals. This is most true in patients with low CD4 cell counts and Acquired 
Immunodeficiency Syndrome (AIDS)-defining conditions (Raines & Lopez 2011). This is 
likely to be caused by the change in their gut microbiome, gut mucosal integrity and 
abnormal humoral and cell-mediated immunity. However this increased risk can also be 
attributed to risk factors such as longer hospital admissions and antibiotic use (especially 
during opportunistic infections) in HIV-seropositive individuals compared to HIV-
seronegative individuals. The clinical presentation, severity and outcomes of CD infection 
appear to be similar in HIV-positive and HIV-negative individuals.   
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1.3 Healthcare-associated infections (HCAIs) versus community-acquired infections 
In general, CD infections are defined as being healthcare-associated infections (HCAIs), 
nosocomial infections or community-acquired infections. Friedman et al. (2002) described 
HCAIs as a category of infections that are present at the time of admission or within hours of 
admission of patients to hospital if the patient had received specific home care (intravenous 
therapy, wound care or home-based nursing care) or attended a haemodialysis clinic in the 
days before the infection, if the patient was hospitalised two or more days in the preceding 90 
days or if they lived in a nursing home or long-term care facility. The latter group are also 
known as nursing home-acquired and long-term care-acquired infections. This definition, 
although originally used to describe bloodstream infections, is widely used in clinical studies 
regardless of the locus of infection. The Infectious Diseases Society of America defined 
hospital-acquired (nosocomial) CD infection  as occurring >48hrs after admission (therefore 
not incubating or present at the time of admission) up to 4 weeks (30 days) after hospital 
discharge (Gupta & Khanna 2014). Community-acquired CD infection is defined as disease 
onset in a person who has had no overnight stay in a healthcare facility within the last 90 
days. This definition does not rule out all contact with the healthcare system (Leffler & 
Lamont 2015). If symptom onset occurs in the community between 4 to 12 weeks after 
discharge from a hospital, it is considered ‘indeterminate’ (Gupta & Khanna 2014). 
Since 2005 a marked rise in the incidence of community-acquired CD has been noted. 
According to Chitnis et al. (2013) an estimated 20 to 25% of CD infections are community-
acquired with an incidence of 20 to 50 cases per 100 000 population in the United States, 
Sweden and England. A South African study in Cape Town identified 59 patients with CD-
associated diarrhoea of which 19 (32.2%) were community-acquired (Rajabally et al. 2013). 
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Community-acquired CD infection tends to affect younger patients with fewer comorbidities 
(Leffler & Lamont 2015). An epidemiologic study undertaken in the UK showed that almost 
all the cases of community-acquired CD infection were <65 years old (Gupta & Khanna 
2014). Despite a lower morbidity and mortality for community-acquired CD infection, up to 
40% of patients will require hospitalization (Leffler & Lamont 2015). The presence of severe 
infection as well as increasing age, increased number of comorbidities and failure to respond 
to therapy predict the need for hospitalization (Gupta & Khanna 2014). 
The study by Chitnis et al. (2013) evaluated out-patient healthcare exposure in patients with 
community-acquired CD infection in the prior 12 weeks. The healthcare exposure was 
separated into 3 categories namely: no exposure, low level exposure (out-patient doctor or 
dentist visit) or high level exposure (surgery, emergency visits, in-patient care without 
overnight stay or health care personnel). It was found that only 18% of patients had no 
healthcare exposure. Identifiable risk factors included exposure to antibiotics, gastric acid 
suppression or household members with active CD infection as person-to-person (faeco-oral) 
transmission is the primary route of transmission rather than zoonotic transmission or food 
contamination (Chitnis et al. 2013; Gupta & Khanna 2014). 
1.4 Severity of disease 
According to the guideline for diagnosis, treatment and prevention of CD infections 
(Surawicz et al.), the infection is considered to be mild to moderate with the presence of 
diarrhoea but without any features of severity. “Severe disease” is considered to be present 
with an albumin of <30g/L plus one of either: WCC ≥15×109/L or abdominal tenderness. The 
disease is considered “severe and complicated” when the patient is admitted to an intensive 
care unit attributable to CD infection, is hypotensive with or without the use of inotropes or 
has any of the following features including: fever ≥38.5°C, ileus or significant abdominal 
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distension (pseudomembranous colitis on endoscopy or toxic megacolon), altered mental 
state, WCC ≥35×109/L or <2×109/L, serum lactate >2.2mmol/L or evidence of end organ 
failure (e.g. requires mechanical ventilation or has renal failure) (Surawicz et al. 2013). 
1.5 Morbidity and mortality 
Mitchell and Gardner (2012) reviewed literature from 2005 to 2011 to find that 15 studies 
indicated a mortality of 15% or greater in CD infection. Another study reviewed 136,877 
admissions to Ottawa Hospital in Canada and found that hospital-acquired CD infection was 
associated with an increased risk of in-hospital death regardless of baseline mortality risk. 
Hospital-acquired CD infection increased the absolute risk of death by approximately 10% 
(Oake et al. 2010). 
In the last few years an increase in the incidence and severity of CD infection has been noted, 
some of which is thought to be related to the emergence of a hypervirulent strain of CD 
(Gould & McDonald 2008). This strain has been termed restriction enzyme analysis type B1, 
North American Pulsed-Field Type 1 (NAP1) and PCR ribotype 027. It produces 16 times the 
concentration of toxin A, 23 times the concentration of toxin B, as well as an additional 
binary toxin rendering it more virulent. The role of this binary toxin has not yet been 
established; however it is associated with more severe diarrhoea. This strain also 
demonstrates high levels of resistance to fluoroquinolones.  
Variables that have been associated with increased mortality include: albumin ≤ 24.5g/L, 
white cell count (WCC) >12×10
9
/L, C-Reactive Protein (CRP ) >228mg/L and respiratory 
rate >17 breaths per minute (Butt et al. 2013). Another study found age >70 years, WCC 
>35×10
9
/L or <4×10
9
/L and cardiorespiratory failure to be independent predictors of 
mortality (Bobo, Dubberke & Kollef 2011).  
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1.6 Treatment 
Metronidazole and vancomycin are the most commonly used antibiotics for the treatment of 
CD infection. Treatment for CD usually involves stopping the offending antibiotics, if 
possible, and initiating therapy with oral metronidazole (500mg 8 hourly) for 10-14 days 
(Collini et al. 2013). In cases of a high clinical suspicion for CD infection, treatment should 
be initiated empirically prior to stool testing. Oral metronidazole at this dose is recommended 
for mild to moderate disease. However, in patients intolerant/allergic to metronidazole or in 
pregnant/breastfeeding females, vancomycin should be used instead (Surawicz et al. 2013). 
Treatment response is when the stool frequency decreases or stool consistency improves and 
parameters of disease severity improve without the development of new features of severity 
(Debast, Bauer & Kuijper 2013). Poor response to metronidazole within 5-7 days should 
prompt a change to vancomycin (Surawicz et al. 2013). 
Severe cases are managed with oral vancomycin (125mg) four times daily (6 hourly) for 10-
14 days as vancomycin has been shown to be superior to metronidazole in the treatment of 
severe disease. When oral antibiotics cannot reach a segment of colon, for example, with a 
Hartman pouch, ileostomy or colon diversion, vancomycin via enema should be added to 
treatment. Patients with “severe and complicated” CD infection should be managed 
supportively and treated with vancomycin 125mg 6 hourly plus intravenous metronidazole 
(500mg 8 hourly). In the case of ileus or toxic megacolon, 500mg vancomycin should be 
given orally 6 hourly as well as 500mg (in 500ml fluid) per rectum plus intravenous 
metronidazole (500mg 8 hourly). Complicated CD infection warrants urgent CT abdomen 
and pelvis and surgical consultation (Surawicz et al. 2013). Probiotics incorporating 
lactobacilli and bifidobacteria have not been shown to be effective in prevention of antibiotic-
associated diarrhoea or in CD-associated diarrhoea (Allen et al. 2013). 
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1.7 Recurrence  
Recurrence is defined by the Infectious Disease Society of America/Society for Healthcare 
Epidemiology of America (IDSA/SHEA) as the presence of diarrhoea with a positive 
Clostridium difficile stool assay within 2–8 weeks from the initial episode (Cohen et al. 
2010). Risk factors for recurrence of CD infection include age ≥65 years, PPI use while on 
treatment for CD, increased hospitalization and prolonged hospital stay, as well as severe 
underlying disease such as chronic renal disease, inflammatory bowel disease and immuno-
compromise (Kelly 2012). In these patients repeated antibiotics are being used; however 
infusion of donor faeces has shown efficacy in treating these patients. Infusion antibodies 
against CD toxins have to be investigated as to whether they are an effective treatment 
strategy (Van Nood et al. 2013). Fidaxomicin is an effective treatment that can be used in 
severe infections as its cure rate has been shown to be equivalent to that of vancomycin. The 
risk of recurrence of disease has been shown to be 15% with fidaxomicin compared to 25% 
with vancomycin. However this reduced rate of recurrence was not seen with the NAP1 PCR 
ribotype 027 strain (Leffler & Lamont 2015). 
1.8 South African perspective 
There are only five Clostridium difficile studies that have been undertaken in South Africa. 
Two of these were in paediatric patients and will not be discussed here. A study was 
undertaken in Pretoria by Storm et al. (2012) where stool samples were analysed for the 
presence of toxin A, B and binary toxin genes. It was found that conventional polymerase 
chain reaction (PCR) testing is useful for detecting all of the toxin genes of CD in stool 
specimens. Toxin A producing strains of CD were found to be the most prevalent in Pretoria 
but may have the potential to acquire binary toxins which may cause severe disease. Another 
study was undertaken in the Vhembe district of Limpopo by Samie et al. (2008). In this 
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study, PCR testing was used to determine the prevalence of toxigenic CD. Out of 322 stools 
collected, 7.1% contained toxigenic CD and 11.4% were associated with diarrhoea. 
Toxigenic CD was found to be more common in individuals older than 50 years (20%), 
followed by the 30-39 year age category (19%). Co-infections were common, in particular, 
with Enterocytozoon bieneusi, Cryptosporidium parvum and Escherichia coli. 
A 2013 study done at Groote Schuur Hospital in Cape Town by Rajabally et al. aimed at 
identifying risk factors and patient outcomes. In that study 58% of patients with CD infection 
were found to be female, 66% had prior antibiotic exposure, 46% had been hospitalised in the 
last 3 months and 24% had concomitant inflammatory bowel disease.  The study found that 
hospital-acquired CD infection was much less common in South Africa (0.87 cases per 1000 
hospitalisations) as compared to the first world (7.4 cases per 1000 hospitalizations). It was 
also reported that although antibiotic use was a major risk factor for nosocomial CD 
infection, most cases of community-acquired CD infection were not associated with antibiotic 
exposure. That study paves the way for further investigation as it begs the question as to what 
else is unique regarding this infection in the South African setting? 
Similar data needed to be reviewed in Johannesburg with regards to understanding patient 
risk factors, presenting features, treatment and outcomes. There is also a need for comparison 
of HIV-positive versus HIV-negative patients and HCAIs versus community-acquired 
infections. Another aspect to consider is the comparison of survivors and non-survivors in 
order to better understand factors affecting the outcome of the condition. 
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2.0 METHODS 
2.1 Study population and data collection methods 
The study was a single-center, retrospective analysis of in-patients with confirmed 
Clostridium difficile infection. The study was conducted at the Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH), a tertiary academic hospital in Gauteng 
Province, South Africa. The study included adult patients (≥18 years) from the infectious 
diseases wards (497 and 587), gastroenterology ward (595) and the intensive care unit (ICU; 
576) during the period of 1 January 2013 to 30 June 2014 with confirmed Clostridium 
difficile infection. A list of all the patients whose stool samples tested Clostridium difficile 
positive at Charlotte Maxeke Hospital during this 18 month time period was obtained from 
the National Health Laboratory Service (NHLS) database and the selected wards were filtered 
out.  Data was collected from hospital records and/or ICU charts obtained from the hospital 
records department. Data was extracted from these documents using a data capturing sheet 
(see Appendix A). Patients with incomplete and missing files were excluded from the study. 
Ethics approval was obtained from the Human Research Ethics Committee of the University 
of the Witwatersrand (see Appendix A). 
2.2 Patient variables collected 
Patient demographics, including age and gender, were recorded. In particular, it was noted 
whether patients were older than 65 years of age or not, as this is a known risk factor for 
Clostridium difficile infection. Patients younger than 18 years of age were excluded from the 
study. The presenting signs and symptoms including watery/bloody diarrhoea, fever (>38°C), 
abdominal pain, nausea, vomiting, loss of appetite, peritonism and ileus were recorded. 
Exposure to antibiotics within the last 30 days and the types of antibiotics were recorded. 
Other risk factors that were recorded included the use of: gastric acid suppressants 
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(antacids/H2 receptor antagonists/PPIs), immunosuppressive drugs (oral or intravenous 
corticosteroids/other), diclofenac, anti-depressants (fluoxetine/mirtazapine/nortriptyline) or 
drugs that cause intestinal stasis e.g. loperamide or opioids 
(morphine/pethidine/codeine/tramadol). 
HIV status, CD4 cell counts, HIV viral loads and the use of anti-retroviral or tuberculosis 
(TB) therapy was recorded. The duration of hospital stay and the number of previous hospital 
admissions were recorded. It was noted whether previous hospital admissions were <2 or ≥2 
days duration and whether they occurred more than or less than 90 days ago. It was also 
noted whether the current CD infection symptoms began prior to or after 48 hours of hospital 
admission. This was used to categorise admissions into either health-care associated 
infections (HCAIs) or community-acquired infections. HCAIs were defined as being present 
at the time of admission or within hours of admission if the patient had received specific 
home care (intravenous therapy, wound care or home-based nursing care) or attended a 
haemodialysis clinic in the days before the infection, if the patient had been hospitalised for 
two or more days in the preceding 90 days or if they lived in a nursing home or long-term 
care facility (Friedman et al. 2002). Hospital-acquired (nosocomial) CD infections were 
defined as those that occurred during a hospital admission beginning >48 hours after 
admission and up to 4 weeks (30 days) after hospital discharge. (Gupta & Khanna 2014). For 
the purpose of the current study, hospital-acquired infections were included together with 
HCAIs. Community-acquired CD infections were defined as disease onset in a person who 
had no overnight stay in a healthcare facility within the last 90 days (Leffler & Lamont 
2015). This definition does not rule out all contact with the healthcare system or acquisition 
in a healthcare facility as patients may have attended out-patient clinics or general 
practitioners. 
12 
 
The presence of certain known severity and mortality indicators were noted including: 
albumin ≤24.5g/L, WCC >12×109/L, respiratory rate >17 breaths per minute, CRP 
>228mg/L, temperature >38.5°C and raised serum creatinine (>90 µmol/L) (Butt et al. 2013). 
Other common laboratory parameters were also noted, including: white cell count, 
haemoglobin, platelet count, sodium, creatinine and albumin. The type of treatment 
administered and duration of treatment was noted from each file. The overall outcome of 
each patient was recorded, namely: death (non-survivors), discharge (survivors) or unknown 
outcome (this included transfers to other hospitals or patients who signed the refusal of 
hospital treatment (RHT) form). 
2.3 Sample size 
Data was collected for 154 patients. Sample size calculations were based on the key research 
questions, namely the between-group tests, which require the application of the chi-square 
test to determine the association between two categorical variables. Based on the 5% 
significance level and 80% power, Table 2.1 shows the sample sizes required for the 
detection of small, medium and large effect sizes. A sample size of 154 was thus adequate to 
detect a medium effect size as most of the comparisons in this study required 2x2 table sizes. 
Table 2.1: Sample sizes required to detect small, medium and large effect sizes in a chi-
square test at the 5% significance level and at 80% power 
Table size (number 
of categories in each 
variable) 
Sample size required 
Large effect size Medium effect size Small effect size 
2 x 2 31 87 785 
3 x 2 39 108 964 
4 x 2 44 122 1091 
5 x 2 48 133 1194 
Sample size calculations were carried out in G*Power (Buchner 2007) 
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2.4 Data analysis 
Categorical variables were summarised in terms of frequency and percentage and were 
tabulated. Continuous variables were summarised in terms of mean and standard deviation or 
median and interquartile range after the inspection of histograms. 
HIV-positive and HIV negative patients were compared in terms of demographics, presenting 
symptoms/signs, risk factors, severity indicators and outcomes. The survivors and non-
survivors were compared in terms of demographics, risk factors, duration of hospital stay, 
previous admissions, treatment type, treatment duration and severity/mortality indicators. The 
chi-square test was used to assess these relationships for categorical variables.  Fisher’s exact 
test was used for 2x2 tables and where the requirements of the chi-square
 
test could not be 
met. The strength of the associations was measured by Cramer’s V and the phi coefficient. 
The scale of interpretation is given in Table 2.2. 
Table 2.2: Strength of association according to Cramer’s V or phi coefficient 
Cramer’s V or phi coefficient Strength of association 
0.5 and above Strong association 
0.3-0.49 Moderate association 
0.1-0.29 Weak association 
Below 0.1 Little or no association 
 
For duration of hospital stay, the comparisons were carried out using the Wilcoxon rank sum 
test. Data analysis was carried out using SAS (version 9.4 for Windows) with the assistance 
of DMSA (Data Management and Statistical Analysis). The 5% significance level was used.  
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3.0 RESULTS 
3.1 Demographics 
Overall 154 patients were included in the study of whom 83/154 (53.8%) were female and 
71/154 (46.1%) were male. The median age was 39 years (interquartile range: 31-52). The 
youngest patient was 19 years old, the oldest patient was 92 years old and 20/154 (13%) 
patients were older than 65 years. In total, 105/154 (68.2%) patients were HIV-positive, 39 
(25.3%) were HIV-negative and 10 (6.5%) were of unknown HIV status.  
3.2 Clinical presentation: signs and symptoms 
The presenting signs and symptoms in patients who were Clostridium difficile positive are 
indicated in Table 3.1. The most common symptom was watery diarrhoea (92.9%) followed 
by fever (27.3%). A single case each of toxic megacolon and pseudomembranous colitis was 
found. 
Table 3.1: Presenting signs and symptoms in patients with Clostridium difficile infection 
Signs and symptoms No of patients out of 154 
(Percentage) 
Watery diarrhoea 143 (92.9%) 
Fever (>38°C) 42 (27.3%) 
Abdominal pain 25 (16.2%) 
Nausea and/or vomiting 18 (11.7%) 
Loss of appetite 16 (10.4%) 
Bloody diarrhoea 9 (5.8%) 
Ileus 3 (1.9%) 
Peritonism 1 (0.6%) 
Toxic megacolon 1 (0.6%) 
Pseudomembranous colitis 1 (0.6%) 
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3.3 Medication as risk factors 
With regards to medications as risk factors for acquiring Clostridium difficile infection, a 
number of the patients had several risk factors, as shown in Table 3.2. Overall, 145/148 
(97.9%) patients had been exposed to antibiotics within the last 30 days, 48/154 (31.2%) had 
been exposed to gastric acid suppressants and 35/154 (22.7%) had been exposed to opioids. 
In total, 54/154 (35.1%) patients had been given immunosuppressants.  
Table 3.2: Medications as risk factors for acquiring Clostridium difficile infection  
Type of medication patients were exposed to 
 
n/N(Percentage) 
Exposure to antibiotics in prior 30 days 
(exposure to antibiotics unknown in 6 patients)  
145/148 (97.9%) 
 
Immunosuppressives  54/154 (35.1%) 
Gastric acid suppression (H2 receptor 
antagonist/PPI/antacid) 
48/154 (31.2%) 
Opioids 35/154 (22.7%) 
Loperamide 1/154 (0.6%) 
Antidepressants 
(mirtazapine/nortryptiline/fluoxetine) 
0/154 (0%) 
Diclofenac 0/154 (0%) 
n = number of patients who were exposed to specific medication, N = total number of patients 
The types of antibiotics, gastric acid suppressants, opioids and immunosuppressives that 
patients had received are shown in Table 3.3. In addition in the table it is indicated whether 
the patients were on TB treatment and/or anti-retroviral therapy. The most common antibiotic 
that had been given was amoxicillin-clavulanic acid (67/145: 46.2%), followed by 
piperacillin-tazobactam (39/145: 26.9%) and ertapenem (35/145: 24.1%). The patients were 
exposed to a median of 2 antibiotics. Of the 48 patients exposed to gastric acid suppressants, 
26 (54.2%) were on an oral PPI and 24 (50%) were on an intravenous PPI. Of the 54 patients 
on immunosuppressants, 39 (72.2%) were on an intravenous corticosteroid. A total of 52.6% 
of patients were on TB therapy and of the 105 HIV-positive patients, 46.7% were on anti-
retroviral therapy. 
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Table 3.3: Types of medications patients with Clostridium difficile infection were exposed to 
Types of medications n/N 
(Percentage)  
Types of antibiotics:  
Amoxicillin-clavulanic acid 67/145 (46.2%)  
Piperacillin-tazobactam 39 /145 (26.9%) 
Ertapenem 35 /145 (24.1%) 
3rd generation cephalosporin 34 /145 (23.4%) 
Fluoroquinolone 19 /145 (13.1%) 
Meropenem 11 /145 (7.6%) 
2nd generation cephalosporin 10 /145 (6.9%) 
4th generation cephalosporin 10 /145 (3.9%) 
Vancomycin 8 /145 (5.5%) 
Clindamycin 5 /145 (3.4%) 
Cloxacillin 3 /145 (2.1%) 
Imipenem 2 /145 (1.4%) 
Exposed to unknown antibiotic 7 /145 (4.8%) 
Exposed to other antibiotic 39 /145 (26.9%) 
Types of immunosuppressives:  
IV corticosteroid 39 /54 (72.2%) 
Oral corticosteroid 8 /54 (14.8%) 
Oral and IV corticosteroid 6 /54 (11.1%) 
Other immunosuppressive 1 /54 (1.9%) 
Types of gastric acid suppressants:  
Oral PPI 26/48 (54.2%) 
IV PPI 24/48 (50.0%) 
Histamine 2 receptor antagonists 1/48 (2.1%) 
Antacid 1/48 (2.1%) 
Types of opioids:  
Tramadol 18 /35 (51.4%) 
Morphine 14 /35 (40.0%) 
Codeine 4 /35 (11.4%) 
Pethidine 1 /35 (2.9%) 
Patients on TB treatment 81 /154 (52.6%) 
HIV-positive patients on ARVs 49 /105 (46.7%) 
IV = intravenous, PPI = Proton Pump Inhibitor, TB = tuberculosis, ARVs = anti-retrovirals, n = number of cases 
receiving the specific drug, N = number of patients exposed to that class of drug. 
3.4 Previous hospital contact 
The number of previous admissions and the number of days admitted to the ward or ICU is 
documented in Table 3.4. Of the 154 patients, 65 (42.2%) had previously been admitted 
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within the last 90 days and 6 (9.2%) had more than one previous admission. The median 
number of days admitted was 17 days (interquartile range: 10-28.5).  Overall, 47/154 (30.5%) 
of patients had been in ICU and the median number of days in ICU was 10 days (interquartile 
range: 5-14). Only 2/154 (1.3%) of infections were identified as community-acquired and 
151/154 (98.1%) of cases were healthcare-associated infections. One patient could not be 
identified as having either a community-acquired or healthcare-associated infection. 
Table 3.4: Previous hospital admissions and number of days patients were admitted to the 
ward/ICU 
Variable n/N 
(Percentage) 
Previously admitted 65/154 (42.2%) 
Previous admissions unknown 14/154 (9.1%) 
Not previously admitted 75/154 (48.7%) 
Of those patient who had been previously admitted (n=65):  
≤90 days ago 63/65 (96.9%) 
>90 days ago 2/65 (3.1%) 
<2 days duration 2/65 (3.1%) 
≥2 days duration 37/65 (56.9%) 
Unknown duration of previous admission 26/65 (40.0%) 
More than one previous admission 6/65 (9.2%) 
Median (IQR) days admitted 17 (10-28.5) 
Duration of current admission unknown 3/154 (1.9%) 
Minimum to maximum number of days admitted 1-144 
No. of patients in ICU 47/154 (30.5%) 
Median (IQR) duration of admission in ICU 10 (5.0-14) 
Minimum to maximum no of days admitted in ICU 1-48 
No. of healthcare-associated infections 151/154 
(98.1%) 
No. of community-acquired infections 2/154 (1.3%) 
Indeterminate if healthcare-associated or community-acquired 1/154 (0.6%) 
Untreated patients that died 12/22 (54.1%) 
Treated patients that died 59/129 (45.7%) 
IQR = interquartile range, ICU = intensive care unit, n = number of patients with that specific variable, N = total 
number of patients. 
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3.5 Laboratory parameters 
The values of common laboratory parameters are indicated in Table 3.5. The median CD4 
cell count for HIV-positive patients in the study was 59×10
6
/L (interquartile range: 13.5 – 
131.5) 
Table 3.5: Laboratory parameters in patients with Clostridium difficile infection 
Lab parameter 
 
Mean (standard deviation)/Median 
(Interquartile range) 
Median WCC (×10
9
/L) 8.26 (5.05-13.49) 
Mean haemoglobin (g/dL) 9.7 (2.2) 
Median platelet count (×10
9
/L) 234 (133-364) 
Mean sodium (mmol/L) 139.7 (75) 
Median creatinine (µmol/L) 73 (50-168.25) 
Median albumin (g/L) 22 (19.5-27.0) 
Median CRP  (mg/L) 113 (66-189) 
Median CD4 (×10
6
/L) 59 (13.5-131.5) 
Median HIV viral load 142195 (343.5-429437) 
 
3.6 Severity indicators 
The frequency of each severity/mortality indicator is documented in table 3.6. Of the 154 
patients, 91 (59.1%) had an albumin of ≤24.5g/L. This was the most common severity 
indicator present in the study population. 
Table 3.6: Severity/mortality indicators in patients with Clostridium difficile infection 
Severity indicator (no of cases in which the laboratory parameter 
was known) 
No of patients 
(Percentage) 
Albumin ≤24.5g/L (147) 91 (59.1%) 
Respiratory rate >17 breaths per minute (154) 77 (50.0%) 
Raised creatinine: >90µmol/L (154) 56 (36.4%) 
WCC >12×10
9
/L (153) 47 (30.5%) 
Temperature >38.5°C (154) 37 (24.0%) 
CRP >228mg/L (141) 15 (9.7%) 
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3.7 Treatment 
Twenty-two (14.3%) patients did not appear to have been treated for Clostridium difficile. 
The medical records of these patients did not indicate any evidence of them having been 
treated for the infection. Eighty-five (66.4%) of the treated patients were treated with oral 
metronidazole 400mg eight hourly and 37 patients (28%), were treated with oral vancomycin. 
Eighty-five (66.4%) of patients were treated for 10-14 days (Table 3.7).  
Table 3.7: Type of treatment and duration of treatment administered for Clostridium difficile 
infection 
Type/duration of treatment 
 
n/N (Percentage)  
Treated patients 128/154 (83.1%) 
Patients not treated 22/154 (14.3%) 
Treatment unknown 4/154 (2.6%) 
Oral metronidazole 400mg 8hrly 85/128 (66.4%) 
Oral and IV metronidazole 34/128 (26.6%) 
Oral metronidazole 800mg 8hrly 5/128 (3.9%) 
IV metronidazole (500mg 8hrly) 4/128 (3.1%) 
Oral vancomycin 125mg 6hrly 18/128 (14.1%) 
Oral vancomycin 250mg 6hrly 14/128 (10.9%) 
Other oral vancomycin dose 5/128 (3.9%) 
Treatment given for 10-14 days 85/128 (66.4%) 
Treatment given for <10 days 40/128 (31.3%) 
Treatment given for unknown duration 3/128 (2.3%) 
Treated until death 49/154 (31.8%) 
IV = intravenous, Other oral vancomycin dose = 1g daily, 500mg 6 hourly (2 patients), 500mg 8 hourly and 
125mg 12 hourly, n = number of patients treated with specific medication/dose, N = total number of treated 
patients. 
 
3.8 Outcomes 
Overall, 73/154 (47.4%) of patients died and 67/154 (43.5%) survived and were discharged. 
The remaining 14 (9%) patients were either transferred to other hospitals or signed the refusal 
of hospital treatment (RHT) form and their outcomes are unknown. These findings are 
demonstrated in Table 3.8.  
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Table 3.8: Outcomes of patients with Clostridium difficile infection 
Outcome  No of patients out 
of 154 (Percentage) 
Death 73 (47.4) 
Discharged 67 (43.5%) 
Transfer 10 (6.5%) 
Unknown 3 (1.9%) 
Signed refusal of hospital treatment form 1 (0.6%) 
  
3.9 Comparison of survivors and non-survivors of Clostridium difficile infection 
When the survivors and non-survivors were compared, no significant differences were found 
with regards to demographics and clinical presentation (signs/symptoms). This is recorded in 
Table 3.9. 
Table 3.9: Comparison of survivors and non-survivors of Clostridium difficile infection with 
regards to demographics and clinical presentation (signs and symptoms) 
Variable Category Overall 
n (%) 
Died 
n (%) 
Survived 
n (%) 
p-value 
N  154 73 67  
Gender Female 83 (53.9) 37 (50.7) 36 (53.7) 0.74 
Male 71 (46.1) 36 (49.3) 31 (46.3) 
Age <65 years 134 (87.0) 62 (84.9) 60 (89.6) 0.46 
≥65 years 20 (13.0) 11 (15.1) 7 (10.4) 
Clinical 
presentation 
(symptoms 
and signs) 
Watery 
diarrhoea 
143 (92.9) 70 (95.9) 59 (88.1) 0.12 
Bloody 
diarrhoea 
9 (5.8) 2 (2.7) 7 (10.4) 0.09 
Fever (>38°C) 42 (27.3) 24 (32.9) 16 (23.9) 0.27 
Abdominal 
pain 
25 (16.2) 9 (12.3) 12 (17.9) 0.48 
Nausea and/or 
vomiting 
18 (11.7) 8 (11.0) 8 (11.9) >0.99 
Loss of 
appetite 
16 (10.4) 8 (11.0) 4 (6.0) 0.37 
Peritonism 1 (0.6) 1 (1.4) 0 (0.0) >0.99 
Ileus 3 (1.9) 3 (4.1) 0 (0.0) 0.25 
Other 2 (1.3) 2 (2.7) 0 (0.0)  
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When comparing the survivors and non-survivors of CD infection, there was no difference in 
terms of exposure to antibiotics, gastric acid suppressants, opioids, immunosuppresants, 
antidepressants, diclofenac or loperamide. This is demonstrated in Table 3.10. 
Table 3.10: Comparison of survivors and non-survivors of Clostridium difficile infection in 
terms of medications as risk factors 
Risk factor Category Overall 
n (%) 
Died 
n (%) 
Survived 
n (%) 
p-value  
N  154 73 67  
Antibiotics in prior 
30 days 
Unknown 6 (3.9) 1 (1.4) 3 (4.5)  
No 3 (1.9) 0 (0.0) 3 (4.5) 0.1 
Yes 145 (94.2) 72 (98.6) 61 (91.0) 
Gastric acid 
suppression 
No 106 (68.8) 50 (68.5) 46 (68.7) >0.99 
Yes 48 (31.2) 23 (31.5) 21 (31.3) 
Opioids No 119 (77.3) 58 (79.5) 49 (73.1) 0.43 
Yes 35 (22.7) 15 (20.5) 18 (26.9) 
Immunosuppressives No 100 (64.9) 43 (58.9) 46 (68.7) 0.29 
Yes 54 (35.1) 30 (41.1) 21 (31.3) 
Anti-depressants  No 154 (100.0) 73 (100.0) 37 (100.0)  
Yes 0 (0.0) 0 (0.0) 0 (0.0) 
Loperamide No 153 (99.4) 73 (100.0) 66 (98.5) 0.48 
Yes 1 (0.6) 0 (0.0) 1 (1.5) 
Diclofenac No 154 (100.0) 73 (100.0) 67 (100.0)  
Yes 0 (0.0) 0 (0.0) 0 (0.0) 
IV = intravenous 
The survivors and non-survivors were also compared in terms of each specific type of 
medication; however no statistically significant differences could be found. This is 
demonstrated in table 3.11. 
 
 
 
 
 
22 
 
Table 3.11: Comparison of survivors and non-survivors of Clostridium difficile infection in 
terms of exposure to specific medications  
Risk factor Category Died 
n (%) 
Survived 
n (%) 
p-value  
N  73 67  
Antibiotic Unknown 5 (6.9) 3 (4.9)  
Amoxicillin-
clavulanic acid 
No 29 (40.3) 32 (52.5) 0.21 
Yes 38 (52.8) 26 (42.6) 
Cloxacillin No 65 (90.3) 57 (93.4) >0.99 
Yes 2 (2.8) 1 (1.6) 
Clindamycin No 66 (91.7) 54 (88.5) 0.18 
Yes 1 (1.4) 4 (6.6) 
Fluoroquinolone No 59 (81.9) 50 (82.0) 0.79 
Yes 5 (6.9) 3 (4.9) 
Piperacillin-
tazobactam 
No 44 (61.1) 45 (73.8) 0.17 
Yes 23 (31.9) 13 (21.3) 
Ertapenem No 51 (70.8) 43 (70.5) 0.84 
Yes 16 (22.2) 15 (24.6) 
Imipenem  No 65 (90.3) 58 (95.1) 0.50 
Yes 2 (2.8) 0 (0.0) 
Meropenem No 60 (80.3) 54 (88.5) 0.54 
Yes 7 (9.7)) 4 (6.6) 
Vancomycin No 63 (87.5) 54 (88.5) >0.99 
Yes 4 (5.6) 4 (6.6) 
2nd generation 
cephalosporin 
No 61 (84.7) 54 (88.5) 0.75 
Yes 6 (8.3) 4 (6.6 
3rd generation 
cephalosporin 
No 46 (63.9) 46 (75.4) 0.22 
Yes 21 (29.2) 12 (19.7) 
4th generation 
cephalosporin 
No 62 (86.1) 54 (88.5) >0.99 
Yes 5 (6.9) 4 (6.6) 
Gastric acid 
suppressant 
    
Antacid No 22 (95.7) 20 (95.2) >0.99 
Yes 1 (4.3) 0 (0.0) 
Histamine 2 receptor 
antagonist 
No 22 (95.7) 21 (100.0) >0.99 
Yes 1 (4.3) 0 (0.0) 
Oral Proton pump 
inhibitor 
No 12 (52.2) 6 (28.6) 0.14 
Yes 11 (47.8) 15 (71.4) 
Intravenous (IV) 
Proton pump inhibitor 
No 11 (47.8) 13 (61.9) 0.38 
Yes 12 (52.2) 8 (38.1) 
Opioids     
Morphine No 7 (46.7) 13 (72.2) Group size too 
small for 
between group 
comparisons 
Yes 8 (53.3) 5 (27.8) 
Codeine No 13 (86.7) 16 (88.9) 
Yes 2 (13.3) 2 (11.1) 
Pethidine No 15 (100.0) 17 (94.4) 
Yes 0 (0.0) 1 (5.6) 
Tramadol No 9 (60.0) 7 (38.9) 
Yes 6 (40.0) 11 (31.1) 
Immunosuppressives     
Oral corticosteroid No 27 (90.0) 17 (81.0) 0.43 
Yes 3 (10.0) 4 (19.0) 
Intravenous 
corticosteroid 
No 6 (20.0) 7 (33.3) 0.34 
Yes 24 (80.0) 14 (66.6) 
Oral and intravenous 
corticosteroid 
No 28 (93.3) 18 (85.7) 0.64 
Yes 2 (6.7) 3 (14.3) 
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Previous hospital admissions, duration of current hospital admission and whether or not 
patients were admitted to the intensive care unit (ICU) or not had no impact on survival of 
patients with Clostridium difficile infection. This is indicated in Table 3.12. 
Table 3.12: Comparison of survivors and non-survivors of Clostridium difficile infection in 
terms of previous hospital admissions, duration of current hospital admission and whether 
they were admitted in the intensive care unit (ICU) or not 
Risk factor Category Died 
n (%) 
Survived 
n (%) 
p-value  
N  73 67  
Previous hospital 
admissions 
Unknown 8 (11.0) 4 (6.0)  
No 39 (53.4) 33 (49.3) 0.48 
Yes 26 (35.6) 30 (44.8) 
Number of previous 
hospital admissions 
1 24 (92.3) 26 (86.7) 0.67 
2 2 (7.7) 4 (13.3) 
Number of days 
currently admitted to 
hospital 
Median 15 18.5 0.13 
Interquartile 
range 
9-28 12-31.5 
Admitted to ICU No 47 (64.4) 52 (77.6) 0.10 
Yes 26 (35.6) 15 (22.4) 
ICU = intensive care unit 
 With regards to the comparison of treatment in the survivors and non-survivors, 16.4% of the 
survivors were not treated for the infection compared to 10.4% of the non-survivors (p = 
0.33).  A greater proportion of the survivors (77.6%) were treated with oral metronidazole 
400mg 8 hourly as compared to the non-survivors (50.8%) (p = 0.0037; phi coefficient = 
0.28).  Furthermore, 23/73 (39%) of the patients who died were treated with oral and 
intravenous metronidazole as compared to only 10/67 (17.2%) of the patients who survived 
(p = 0.013; phi coefficient = 0.24). Overall, 98% of the survivors had been treated for 10 or 
more days as compared to only 39% of those who died (p <0.0001; phi coefficient = 0.64). 
This is demonstrated in table 3.13.  
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Table 3.13: Comparison of treatment type and duration in survivors and non-survivors of 
Clostridium difficile infection 
 Category Died 
n (%) 
Survived 
n (%) 
p-value  
N  73 67  
Treatment 
(n = 128) 
Unknown 2 (2.7) 2 (3.0)   
No 12 (16.4) 7 (10.4) 0.33 
Yes 59 (80.8) 58 (86.6) 
Type of treatment 
 
Oral 
metronidazole 
400mg 8 hrly 
30 (50.8) 45 (77.6)  0.0037 (phi=0.28) 
Oral 
metronidazole 
800mg 8hrly 
3 (5.1) 2 (3.4) >0.99 
IV 
metronidazole 
3 (5.1%) 1 (1.7) 0.62 
Oral and IV 
metronidazole 
23 (39) 10 (17.2) 0.013 (phi=0.24) 
Oral 
vancomycin 
125mg 8hrly 
8 (13.6) 10 (17.2) 0.62 
Oral 
vancomycin 
250mg 8 hrly 
8 (13.6) 6 (10.3) 0.78 
Other oral 
vancomycin 
dose 
2 (3.4) 2 (3.4)  >0.99 
Treatment 
duration 
<10 days 34 (60.7) 1 (1.7) <0.0001 (phi=0.64) 
10-14 days 22 (39.3) 57 (98.3) 
IV = intravenous, Other oral vancomycin dose = 1g daily, 500mg 6 hourly (2 patients), 500mg 8 hourly and 
125mg 12 hourly. 
 
When comparing the severity indicators in the survivors and non-survivors, the patients who 
died had a greater number of severity indicators (p = 0.0006; Cramer’s V = 0.39). Overall, 
71.2% of the non-survivors had a respiratory rate above 17 breaths per minute compared to 
only 28.4% of the survivors (p <0.0001; phi coefficient = 0.43). Raised serum creatinine 
tended to be more common in non-survivors (33%) compared to survivors (20%) however 
this finding did not reach statistical significance (p = 0.08). This is indicated in Table 3.14. 
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Table 3.14: Comparison of survivors and non-survivors of Clostridium difficile infection in 
terms of type and number of severity indicators 
Severity 
indicator 
Category Died 
n (%) 
Survived 
n (%) 
p-value  
N  73 67  
Number of 
severity 
indicators present 
Unknown 2 (2.7) 14 (20.9)  
0 1 (1.4) 12 (17.9) 0.0006 (V=0.39) 
1 12 (16.4) 14 (20.9) 
2 23 (31.5) 13 (19.4) 
3 18 (24.7) 8 (11.9) 
4 or more 17 (23.3) 6 (9.0) 
Albumin ≤24.5 
g/L 
unknown 2 (2.7) 4 (6.0)   
no 25 (34.2) 28 (41.8) 0.29 
yes 46 (63.0) 35 (52.2) 
WCC >12×10
9
/L unknown 0 (0.0) 1 (1.5)   
no 46 (63.0) 51 (76.1) 0.1 
yes 27 (37.0) 15 (22.4) 
Respiratory rate 
>17 breaths per 
minute 
no 21 (28.8) 48 (71.6) <0.0001 (phi=0.43) 
yes 52 (71.2) 19 (28.4) 
CRP >228 mg/L unknown 0 (0.0) 12 (17.9)   
no 64 (87.7) 52 (77.6) 0.23 
yes 9 (12.3) 3 (4.5) 
Temp >38.5 °C no 51 (69.9) 54 (80.6) 0.17 
yes 22 (30.1) 13 (19.4) 
Raised serum 
creatinine 
(>90µmol/L) 
no 40 (54.8) 47 (70.1) 0.08 
yes 33 (45.2) 20 (29.9) 
 
Figure 3.1 illustrates a greater number of severity indicators present in the non-survivors as 
compared to the survivors. Therefore, these severity indicators may be synonymous with 
mortality indicators for CD infection. 
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Figure 3.1: Comparison of survivors and non-survivors of Clostridium difficile in terms of 
the number of severity indicators in each group 
 
3.10 Comparison of HIV-positive and HIV-negative patients with Clostridium difficile 
infection 
Table 3.15 demonstrates the comparison of HIV-negative and HIV-positive patients with 
Clostridium difficile infection in terms of demographics and clinical presentation. With 
regards to the HIV-negative patients, 44% were 65 years and older as compared to none of 
the HIV-positive patients (p <0.0001; phi coefficient = 0.6). A higher proportion of HIV-
negative patients (13%) had bloody diarrhoea as compared to only 2% of the HIV-positive 
patients (p = 0.016; phi coefficient = 0.23). 
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Table 3.15: Comparison of HIV-positive and HIV-negative patients with Clostridium 
difficile infection in terms of demographics and clinical presentation (signs and symptoms). 
Variable Category Overall 
n (%) 
HIV-
negative 
n (%) 
HIV-
positive 
n (%) 
p-value 
N  154 39 105  
Gender Female 83 (53.9) 19 (48.7) 59 (56.2) 0.46 
Male 71 (46.1) 20 (51.3) 46 (43.8) 
Age <65 years 134 (87.0) 22 (56.4) 105 (100.0) <0.0001 
(phi=0.6) ≥65 years 20 (13.0) 17 (43.6) 0 (0.0) 
Clinical 
presentation 
(symptoms 
and signs) 
Watery 
diarrhoea 
143 (92.9) 36 (92.3) 99 (94.3) 0.7 
Bloody 
diarrhoea 
9 (5.8) 5 (12.8) 2 (1.9) 0.016 
(phi=0.23) 
Fever (>38°C) 42 (27.3) 7 (17.9) 33 (31.4) 0.14 
Abdominal 
pain 
25 (16.2) 7 (17.9) 16 (15.2) 0.8 
Nausea and/or 
vomiting 
18 (11.7) 2 (5.1) 14 (13.3) 0.24 
Loss of 
appetite 
16 (10.4) 1 (2.6) 15 (14.3) 0.07 
Peritonism 1 (0.6) 0 (0.0) 1 (1.0) >0.99 
Ileus 3 (1.9) 0 (0.0) 2 (1.9) >0.99 
Other 2 (1.3) 1 (2.6) 1 (1.0) 0.47 
 
Table 3.16 demonstrates the comparison of HIV-negative and HIV positive patients in terms 
of medications as risk factors for Clostridium difficile. All of the HIV-positive patients had 
been exposed to antibiotics within the last 30 days as compared to 92% of the HIV-negative 
patients (p = 0.018; phi coefficient = 0.25). There was no difference between the exposure to 
each individual antibiotic in HIV-negative and HIV-positive patients. There was no 
significant difference in the exposure to opioids, immunosuppressives, diclofenac or 
antidepressants between HIV-negative and HIV-positive patients. Overall, 51% of the HIV-
negative patients had been exposed to gastric acid suppressants as compared to a smaller 
proportion (21%) of HIV-positive patients (p = 0.008; phi coefficient = 0.3). In particular, 
exposure to intravenous PPIs was higher amongst HIV-negative patients (75%), compared to 
HIV-positive patients (36%) (p = 0.016; phi coefficient = 0.39). 
28 
 
Table 3.16: Comparison of HIV-positive and HIV-negative patients with Clostridium 
difficile infection in terms of medications as risk factors 
Risk factor Category Overall 
n (%) 
HIV-
negative 
n (%) 
HIV-
positive 
n (%) 
p-value  
N  154 39 105  
Antibiotics in prior 
30 days 
Unknown 6 (3.9) 2 (5.1) 3 (2.9)  
No 3 (1.9) 3 (7.7) 0 (0.0) 0.018 (phi 
= 0.25 Yes 145 (94.2) 34 (87.2) 102 (97.1) 
Gastric acid 
suppression 
No 106 (68.8) 19 (48.7) 83 (79.0) 0.008 (phi 
= 0.30 Yes 48 (31.2) 20 (51.3) 22 (21.0) 
Oral PPI No 22(45.8) 13 (65.0) 8 (36.4) 0.12 
Yes 26 (54.2) 7 (35.0) 14 (63.6) 
IV PPI No 24 (50.0) 5 (25.0) 14 (63.3) 0.016 (phi 
= 0.39) Yes 24 (50.0) 15 (75.0) 8 (36.4) 
Opioids No 119 (77.3) 29 (74.4) 83 (79.0) 0.65 
Yes 35 (22.7) 10 (25.6) 22 (21.0) 
Immunosuppressives No 100 (64.9) 29 (74.4) 63 (60.0) 0.12 
Yes 54 (35.1) 10 (25.6) 42 (40.0) 
Anti-depressants  No 154 (100.0) 39 (100.0) 105 
(100.0) 
 
Yes 0 (0.0) 0 (0.0) 0 (0.0) 
Loperamide No 153 (99.4) 39 (100.0) 104 (99.0) >0.99 
Yes 1 (0.6) 0 (0.0) 1 (1.0) 
Diclofenac No 154 (100.0) 39 (100.0) 105 
(100.0) 
 
Yes 0 (0.0) 0 (0.0) 0 (0.0) 
PPI = proton pump inhibitor, IV = intravenous 
Table 3.17 indicates the comparison of the types of severity indicators and the number of 
severity indicators in HIV-positive and HIV-negative patients with Clostridium difficile 
infection. Overall, HIV-negative patients tended to have a higher number of severity 
indicators compared to HIV-positive patients (p = 0.011; Cramer’s V = 0.32). A higher 
proportion of HIV-negative patients (61.5%) had an elevated WCC compared to HIV-
positive patients (17.1%) (p <0.0001; phi coefficient = 0.43). Similarly, a higher number of 
HIV-negative patients had an elevated respiratory rate (69.2%) compared to HIV-positive 
patients (43.8%) (p = 0.0085; phi coefficient = 0.23). HIV-negative patients also more 
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commonly had elevated temperatures (41%) compared to HIV-positive patients (19%) 
(p=0.0095; phi coefficient = 0.23).  
Table 3.17: Comparison of HIV-positive and HIV-negative patients with Clostridium 
difficile infection in terms of type and number of severity indicators 
Severity 
indicator 
Category Overall 
n (%) 
HIV-
negative 
n (%) 
HIV-
positive 
n (%) 
p-value  
N  154 39 105  
Number of 
severity 
indicators present 
Unknown 18 (11.7) 2 (5.1) 15 (14.3)  
0 13 (8.4) 2 (5.1) 10 (9.5) 0.011 
(V=0.32) 1 31 (20.1) 4 (10.3) 24 (22.9) 
2 38 (24.7) 8 (20.5) 28 (26.7) 
3 27 (17.5) 9 (23.1) 16 (15.2) 
4 or more 27 (17.5) 14 (35.9) 12 (11.4) 
Albumin ≤24.5 
g/L 
unknown 7 (4.5) 1 (2.6) 6 (5.7)   
no 56 (36.4) 15 (38.5) 35 (33.3) 0.69 
yes 91 (59.1) 23 (59.0) 64 (61.0) 
WCC >12×10
9
/L unknown 1 (0.6) 0 (0.0) 1 (1.0)   
no 106 (68.8) 15 (38.5) 86 (81.9) <0.0001 
(phi=0.43) yes 47 (30.5) 24 (61.5) 18 (17.1) 
Respiratory rate 
>17 breaths per 
minute 
no 77 (50.0) 12 (30.8) 59 (56.2) 0.0085 
(phi=0.23) yes 77 (50.0) 27 (69.2) 46 (43.8) 
CRP >228 mg/L unknown 13 (8.4) 1 (2.6) 11 (10.5)   
no 126 (81.8) 35 (89.7) 82 (78.1) 0.55 
yes 15 (9.7) 3 (7.7) 12 (11.4) 
Temp > 38.5 °C no 117 (76.0) 23 (59.0) 85 (81.0) 0.0095 
(phi=0.23) yes 37 (24.0) 16 (41.0) 20 (19.0) 
Raised serum 
creatinine 
(>90µmol/L) 
no 98 (63.6) 22 (56.4) 70 (66.7) 0.33 
yes 56 (36.4) 17 (43.6) 35 (33.3) 
 
Figure 3.2 illustrates the greater number of severity indicators present in HIV-negative 
patients with Clostridium difficile infection. 
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Figure 3.2: Comparison of HIV-negative and HIV-positive patients with Clostridium difficile 
infection in terms of number of severity indicators in each group 
 
Overall, there was no significant difference in survival of HIV-negative and HIV-positive 
patients with Clostridium difficile infection. This is demonstrated in table 3.18. 
Table 3.18: Comparison of outcomes in HIV-positive and HIV-negative patients with 
Clostridium difficile infection 
Outcome Category Overall 
n (%) 
HIV-
negative 
n (%) 
HIV-
positive 
n (%) 
p-value  
N  154 39 105  
Outcome Unknown 
(includes 
transfer and 
RHT) 
14 (9.1) 3 (7.7) 9 (8.6)   
Died 73 (47.4) 22 (56.4) 49 (46.7) 0.33 
Survived 67 (43.5) 14 (35.9) 47 (44.8) 
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4.0 DISCUSSION 
In general, the major findings of the study are as follows. The study population was younger 
than the expected age of patients at risk for CD infection.  The patients commonly presented 
with the usually described symptoms and signs of CD infection in particular, diarrhoea and 
fever. Patients also demonstrated the commonly known risk factors for CD infection 
including: exposure to antibiotics in the prior 30 days and exposure to gastric acid 
suppressants (in particular PPIs), immunosuppressants or opioids. Patients often had one or 
more previous hospital admissions (42.2% of patients) and often had prolonged hospital 
stays. There was a clear predominance of HCAIs with only two identifiable cases of 
community-acquired CD infection. The most commonly identified severity indicator was an 
albumin of ≤24.5g/L and non-survivors tended to have a greater number of severity 
indicators. The overall mortality of patients with CD infection in this study is significantly 
higher than expected as overall 47.4% of patients died. Survivors were most commonly 
treated with metronidazole 400mg administered 8 hourly for a duration of more than 10 days. 
When comparing HIV-positive patients with HIV-negative patients, the latter patients tended 
to have more bloody diarrhoea and more exposure to gastric acid suppressants in particular, 
intravenous PPIs.  HIV-negative patients tended to have a greater number of severity 
indicators and more commonly had an elevated WCC, respiratory rate and temperature. 
The age of the patients was lower than has been described in some previous studies. The 
median age in this study was 39 years which is the same as the median age in the South 
African study by Rajabally et al. (2013) but much younger than the mean age of 70.8 years in 
the Canadian study by Oake et al. (2010). Overall only 13% of patients were found to be 
older than 65 years which is lower, than expected since age above 65 years is considered a 
risk factor for CD infection (Bobo, Dubberke & Kollef 2011).  This younger median age in 
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the South African studies is almost certainly due to the large number of HIV-positive patients 
within the study populations.  
The patients in the current study were exposed to several well known risk factors for CD 
infection such as antibiotic use in the prior 30 days. This risk factor was present in 97.6% of 
study patients, making it by far the most common risk factor. This begs the question as to 
whether the antibiotics were truly warranted in these patients in the first place considering the 
risk of CD infection. Although some patients were exposed to the common antibiotic culprits 
such as the fluoroquinolones, cephalosporins and clindamycin (Bobo, Dubberke & Kollef 
2011), the most common antibiotics that patients had been previously exposed to in this study 
were amoxicillin-clavulanic acid and piperacillin-tazobactam. Regardless of the antibiotic 
type used, it is essential for clinicians to have a more circumspect approach when prescribing 
antibiotics to patients since their use is not without significant risks.  
Patients commonly had previous hospital admissions within the prior 90 days and the median 
number of days admitted was 17 days. Only 18 (11.6%) patients had been admitted for less 
than 7 days. This mirrors the study by Oake et al. (2010) which demonstrated that the 
majority of hospital-acquired CD is identified after the 7th day of hospital admission.  
In this study, 47.4% of patients died. This reflects a significantly higher mortality rate than 
the reported 20% in the Cape Town study by Rajabally et al. (2013) and the study by Mitchell 
and Gardner (2012), which reported in-hospital mortality rates ranging between 8 and 37%. 
The reason for this increased mortality rate at the CMJAH is unknown and further studies 
would be required to assess possible causes. While it may be interesting to suggest that the 
high mortality rate may be due to the high prevalence of HIV infection in the current study 
population, as indicated below, the mortality in HIV-positive  and HIV-negative cases was 
not significantly different.  
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When comparing survivors and non-survivors in the current study, there were no significant 
differences in the demographics, clinical presentation or the risk factors present.  Age above 
70 years has been associated with increased mortality (Bobo, Dubberke & Kollef 2011), 
however this was not apparent in this study due to the low median age of the study population 
and the few numbers of patients that were of that age. Corticosteroid use has been shown to 
increase short-term mortality in hospitalised patients with CD infection, however this was not 
found in the current study (Gupta & Khanna 2014). 
The survivors in this study had more commonly been treated with oral metronidazole 400mg 
8 hourly than the non-survivors. This does not necessarily indicate that there is an improved 
outcome of CD infections with the use of oral metronidazole but may simply indicate that 
patients who were given oral metronidazole were likely to be those who only had mild to 
moderate disease in whom better outcomes may have been predictable from the start. 
Furthermore, a greater number of non-survivors were treated with a combination of oral and 
intravenous metronidazole compared to the survivors. Again, this may not necessarily reflect 
a poorer outcome with this treatment regimen but may indicate patients with severe disease 
and increased severity who were given a combination of oral and intravenous therapy, and 
had a poorer prognosis from the start. As expected, the non-survivors tended to have a greater 
number of severity indicators which supports the findings of Butt et al. (2013). Therefore, 
these severity indicators could also be referred to as mortality indicators.  
It is important to note that none of the patients in this study were treated with metronidazole 
500mg administered 8 hourly as recommended by guidelines (Surawicz et al. 2013); instead 
the dose used was 400mg administered 8 hourly. This was likely because this is the 
formulation of metronidazole available at this hospital. Further studies would be required to 
determine if this small change in dosage has any implication on clinical response or outcome. 
The patients with ileus, toxic megacolon and pseudomembranous colitis were not managed 
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with rectally administered vancomycin as recommended. Some patients however, did receive 
high doses of vancomycin (with intravenous metronidazole). A dose commonly administered 
was 250mg 6 hourly rather than 500mg 8 hourly of vancomycin. The survivors were more 
commonly treated for longer as compared to the non-survivors. However, this may be the 
case because many patients died before the treatment was completed. It was noted that in 
most cases, treatment for CD infection was initiated whilst continuing other antibiotics. It is 
usually recommended that antibiotics other than metronidazole or vancomycin be stopped 
however; this may not have been possible due to the ongoing treatment of other concomitant 
life-threatening infections (Collini et al. 2013).  
Furthermore, in 14.3% of patients, the medical records did not indicate any evidence of the 
patients having been treated for CD infection. Possible reasons for this may be due to death, 
discharge or refusal of hospital treatment among the patients prior to initiation of treatment 
for CD infection. Another possibility may be lack of follow up of results of stool specimens 
sent. As indicated above the overall mortality rate of the study population was 47.4% being 
54.5% in the untreated patients and 45.7% in the treated patients. This was not significantly 
different. However it cannot be determined whether any of these deaths were solely due to 
CD disease. 
Interestingly, only two patients (1.3%) were identified as having community-acquired CD 
infection. This is much lower than the 32% found in a previous South African study 
(Rajabally et al. 2013) and the 20 to 50 cases per 100 000 population in the United States, 
Sweden and England (Chitnis et al. 2013). The reasons for this are uncertain. It is possible 
that this may be due to community-acquired CD infections being much milder, and therefore 
these patients would be treated as out-patients and not in a tertiary hospital such as CMJAH; 
however the current study only investigated CD infection in the hospital setting.  
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Overall 68.1% of patients were HIV-positive and only 46.7% of these patients were on anti- 
retroviral therapy. The median CD4 cell count of the HIV-seropositive group was 59 
(x10
6
/L). This may demonstrate the apparent susceptibility of HIV-positive patients with low 
CD4 cell counts to CD infection presumably due to their abnormal humoral or cell-mediated 
immunity and altered gut microbiome as described by Raines and Lopez (2013). These 
patients are also more likely to have recurrent opportunistic infections, requiring frequent 
contact with the healthcare system and recurrent antibiotic exposure. Those authors suggested 
that the risk of CD in HIV-positive patients was twice that of HIV-negative patients. 
According to Statistics South Africa, the prevalence of HIV-positive patients in the country 
during 2013 and 2014 was 18.7% and 18.8% respectively (Statistics South Africa 2014). As 
such, if HIV infection was not a risk factor for CD infection, we would have expected a 
similar rate of HIV infection in our study population.  However, the prevalence of HIV-
positive patients in the current study was 68.1%. This may suggest that the risk of CD 
infection in HIV-positive patients is more than 3.5 fold higher than that of HIV-negative 
patients in this study. However, this may also simply be a reflection of the higher HIV 
prevalence among hospital in-patients.  
More than half of the current study patients were on TB therapy; however this may be 
reflective of the types of patients seen in the specific wards assessed in this study rather than 
it being a risk factor for acquiring CD. In this regard, ward 487 and 587 are infectious 
diseases wards to which TB patients (especially sputum positive TB patients) are mainly 
admitted.  
When comparing the HIV-positive patients with CD to the HIV-negative patients, as 
mentioned before, HIV-negative patients more commonly had bloody diarrhoea. HIV-
negative patients were also more commonly exposed to gastric acid suppressants, and in 
particular intravenous PPIs. All of the HIV-positive patients were exposed to antibiotics 
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within the prior 30 days compared to 92% of HIV-negative patients. There was no difference 
in the clinical presentation or outcomes of HIV-positive and HIV-negative patients which is 
similar to the findings of by Raines & Lopez (2011). HIV-negative patients had a greater 
number of severity indicators and more commonly had elevated WCC (>12 × 10
9
/L), 
respiratory rates (>17 breaths per minute) and temperatures (>38.5°C). This could possibly be 
explained by their ability of HIV-negative patients to mount a better immune response 
against the infection than HIV-positive patients. 
This study has some potential limitations. Firstly, the study was retrospective in design and 
therefore not all data that we wished to collect may have been available. However, patients 
whose files were missing, or those who had substantial data missing from their files were 
excluded.  Fortunately most of the records of the patients in this study could easily be traced. 
The study was a single-centre study selecting only patients admitted to a tertiary hospital, 
with a large proportion of patients coming from the infectious diseases wards. This may have 
biased the patient profile and characteristics and therefore it is not clear whether the findings 
are generalizable to the general population. The strengths of this study lie in its successful 
retrieval of most clinical data required and its large sample size which allowed for 
comparisons to be made between the survivors and non-survivors and the HIV-seropositive 
and HIV-seronegative groups. 
In future it would be of benefit to include out-patients as well as in-patients with CD infection 
in the hope of capturing more patients with community-acquired CD infections. This would 
allow for comparisons between community-acquired and healthcare-associated infections in 
order to better understand the characteristics of community-acquired CD infections. It would 
also be beneficial to include a population outside of the infectious diseases wards (perhaps 
including surgical wards) to broaden the patient profile. As mentioned previously, further 
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studies would be required to investigate possible causes for the high mortality rate found in 
this study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
5.0 CONCLUSION 
In general, the patients in this study with CD infection were younger than those described in 
non-South African studies, but comparable to that of other South African studies. The 
mortality of patients with CD was found to be much higher in Charlotte Maxeke Hospital; the 
reason which is currently unknown. The study solidified and reinforced evidence for the 
previously known risk factors for CD infection. These risk factors included: exposure to 
antibiotics, immunosuppressives, gastric acid suppressants, opioids and multiple or prolonged 
admissions. Similarly, patients presented with common signs and symptoms and there was no 
difference in the clinical presentation of the survivors and non-survivors or the HIV-positive 
and HIV-negative patients. There were only two identifiable cases of community-acquired 
CD infection which is much lower than what has been reported in previous local and 
international studies. WCC >12×10
9/L, albumin ≤24.5g/L, temperature >38.5°C, respiratory 
rate >17 breaths per minute and raised serum creatinine (>90µmol/L) were found to be 
important features of severity that could be used to predict mortality. The non-survivors had 
greater number of severity indicators than the survivors. There was no difference in the 
outcomes of HIV-positive and HIV-negative patients. This study paves the way for further 
investigation as there as still many unanswered questions regarding the characteristics of 
patients with community-acquired CD infections and the reasons for the increased mortality 
at this Johannesburg hospital. 
Considering the high mortality of the disease, practicing clinicians need to be aware of risk 
factors for this infection, avoiding them where possible. Effective antibiotic stewardship is 
essential to avoid unnecessary exposure of patients to antibiotics. Furthermore, the presence 
of characteristic symptoms should prompt early diagnosis of CD infection in high risk 
patients with early initiation of appropriate treatment. 
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6.0 APPENDIX A 
Study Number: ________ 
Demographics 
Gender Male 
 
 
Female 
 
 
  
Age Value 
 
 
≥65 years 
 
 
<65 years 
 
 
 
Symptoms/signs present 
Watery diarrhoea  
Bloody diarrhoea  
Fever  
Abdominal pain  
Nausea and/or vomiting  
Loss of appetite  
Peritonism/acute abdomen  
Ileus  
Other  
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Medications as risk factors 
Exposure to 
antibiotics in the 
prior 30  days 
No  Yes  Unknown  
 Amoxicillin-
clavulanic acid 
  
Piperacillin-
tazobactam 
 
Ertapenem  
Imipenem  
Meropenem  
2
nd
 Generation 
cephalosporin 
 
3
rd
 Generation 
cephalosporin 
 
4
th
 Generation 
cephalosporin 
 
Fluoroquinolone  
Clindamycin  
Cloxacillin  
Vancomycin  
Other  
Unknown  
 
 
Gastric acid 
suppression 
No  Yes  Unknown  
 Antacid   
H2 rec 
antagonist 
 
Oral PPI  
IV PPI   
Diclofenac No  Yes  Unknown  
Opioids No  Yes  Unknown  
Codeine? 
Pethidine? 
Morphine? 
Tramadol? 
  
 
 
 
Immunosuppressive 
drugs 
No   Yes  Unknown  
 Steroid 
IV? 
Oral? 
Other? 
  
  
  
  
Mirtazepine/nortrypti
line/fluoxetine 
No  Yes  Unknown  
Loperamide No  Yes  Unknown  
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Other medications 
 No Yes Unknown 
On TB treatment    
On anti-retrovirals    
 
HIV 
HIV Negative Positive Unknown 
   
 
Community-acquired infection or healthcare-associated infection 
Previously admitted? Yes  No  Unknown  
>90 days 
ago  
   
≤90 days 
ago 
 
Duration  
 <2 days 
≥2 days 
   
    
 
Current admission Number of days Unknown 
Duration of 
hospital stay 
 
Ward:_____ 
 
Duration of ICU 
stay 
  
 
Healthcare-associated infection Community-acquired 
infection 
Unknown 
Admitted in last 90 days    
Nosocomial (>48hrs after 
admission) 
 
Nursing home  
Home-based care  
Long-term care facility  
Health care worker  
Out-patient – 
chemotherapy/dialysis 
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Treatment 
Drug Yes Dose and duration 
Oral Metronidazole   
Intravenous Metronidazole   
Oral and IV Metronidazole   
Oral Vancomycin   
Other  Which other? 
Unknown   
 
Indicators of severity 
 Yes No Value Unknown 
Albumin ≤24.5 (g/L)     
WCC>12 (x10
9
/L)     
Respiratory rate>17 (bpm)     
CRP>228 (mg/L)     
Temperature>38.5 (°C)     
Raised serum creatinine 
(µmol/L) 
    
 
Other blood parameters 
 Value Unknown 
WCC (x10
9
/L)   
Hb (g/dL)   
Platelets (x10
9
/L)   
Sodium (mmol/L)   
Creatinine (µmol/L)   
Albumin (g/L)   
CD4 count (if HIV positive)   
HIV viral load (if HIV 
positive) 
  
 
Outcome 
Outcomes Death Survival (discharge) Unknown  
  Transfer 
Signed RHT 
Outcome unknown 
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